RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies
Blood (2020) 136 (Supplement 1): 40.
Currently there are no citedby results. Try again later.
